Organometallic complexes offer the prospect of targeting multiple pathways that are important in cancer biology. Here, the preclinical activity and mechanism(s) of action of a silver-bis(N-heterocyclic carbine) complex (Ag8) were evaluated. Ag8 induced DNA damage via several mechanisms including topoisomerase I/II and thioredoxin reductase inhibition and induction of reactive oxygen species. DNA damage induction was consistent with cytotoxicity observed against proliferating cells and Ag8 induced cell death by apoptosis.
Introduction
An increased understanding of the molecular and cellular biology of cancer has led to an explosion of research into targeted therapies. For certain cancers harbouring particular genetic lesions, targeted therapies have led to significant improvements in outcomes but their use is not without significant limitations. Resistance to treatment remains a significant problem [1] and novel strategies are required to tackle the challenges of tumour plasticity and heterogeneity that promote the development of resistance [2] . One such strategy that is particularly applicable to complex diseases such as cancer is the development of a single drug that targets multiple pathways, an approach known as polypharmacology [3, 4] . This approach has the potential to target biologically important networks thereby reducing the impact of plasticity and heterogeneity but it carries the inherent risk of widespread toxicity.
The challenge is to identify multi-targeted agents that exhibit selectivity for cancer cells over normal cells [5] .
Within this context, there is resurging interest in organometallic complexes following the demonstration that they can target multiple biochemical pathways with cytotoxic activity that is independent of binding to nucleic acids [6] . Metal complexes with N-heterocyclic carbene (NHC) ligands have emerged as an interesting class of organometallic compounds that have anti-microbial and anti-cancer activity [7] . Gold-NHC complexes have been the focus of research into new anti-cancer drugs but these have shown undesirable toxicity in vivo including oxidative damage to the heart and reproductive toxicity in rats [8] . In contrast to gold-NHC complexes, silver-NHC complexes have the potential advantage of reduced toxicity as silver inherently lacks toxicity. This together with the increased stability of silver-NHC complexes make this class of compound particularly attractive as potential anti-cancer drugs [9] . We recently reported the synthesis and initial evaluation of a series of novel silver-NHC complexes that demonstrated cytotoxic activity against MCF7 (human breast carcinoma) and DLD-1 (human colo-rectal carcinoma) cell lines in vitro [10] . Of these compounds, Ag(NHC)2AgBr2 (Ag8, Figure 1 ) was identified as suitable for further evaluation. The purpose of this study was to determine the mechanism(s) of action of Ag8 in the context of identifying a multi-targeted agent that retained selectivity for cancer as opposed to non-cancer cells.
Material and Methods

Compounds:
Ag8 was synthesised as described previously [10] . Cisplatin, etoposide, temozolomide (TMZ) and NU1025 were obtained from Sigma Aldrich (Poole, Dorset, UK).
Cell Lines:
A panel of 16 human cancer and 3 human non-cancer cells was selected for this study, details of which are presented in Table S1 . Cells were cultured in complete medium with appropriate supplements as recommended by ATCC or ECACC.
Chemosensitivity studies:
Cell lines were seeded in 96-well plates at 2000 cells/well and allowed to adhere overnight. Cells were exposed to a range of drug concentrations for 96 h after which cell survival was determined using the MTT assay [11] . The selectivity index (SI) was defined as the IC50 for non-cancer cells divided by the IC50 for cancer cells (values >1 indicating selectivity for cancer cells). Ag8 was also submitted to the National Cancer Institute (Bethesda, USA) for evaluation in the NCI60 cell line panel (NSC 767019).
Inhibition of Thioredoxin Reductase 1 (Trx-R):
The effect of Ag8 on Trx-R activity was determined using the substrate 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) as described elsewhere [12, 13] . Inhibition of Trx-R activity in Ag8 treated samples was calculated as a percentage of enzyme activity of vehicle treated controls.
Detection of Reactive Oxygen Species (ROS):
Cells were seeded at a density of 3x10 6 in 10cm 2 tissue culture dishes and allowed to adhere overnight. Cells were then treated for 30 minutes with cisplatin (10µM), Ag8 (10µM) or appropriate vehicle controls, washed twice with PBS, and labelled with H2-DCFDA (4µM) (Life Technologies) at 37 C in PBS for 30 minutes. Cells were then washed with ice-cold with PBS before trypsinisation and resuspension in ice-cold PBS for immediate analysis for ROS levels by flow cytometry.
Effect of the anti-oxidant N-acetyl-cysteine (NAC) on the cytotoxic activity of Ag8:
Ovarian cancer cells were pre-treated for 1 h with NAC (1 mM) followed by cisplatin or Ag8 in 1mM NAC for a further 72 h. Total cell biomass was assessed using the colorimetric CellTiter 96® AQueous One Solution Cell proliferation assay (Promega).
Detection of stress-activated protein kinases:
Cells were treated for 0, 1.5, 3 and 6 hours with either cisplatin (10µM) or Ag8 (10µM), lysed and processed for SDS-PAGE and immunoblotting using antibodies for p-JNK, pSAPK/JNK, p-38, p-38 MAPK and -actin as previously described [14] .
Induction of apoptosis:
Apoptosis was detected using the Annexin-V-FLUOS Staining Kit (Roche) as previously described [15] . Briefly, A2780 and A2780cis/CP70 cells were seeded at 1x10 5 cells/well in 6 well plates, incubated overnight at 37 C and exposed to Ag8 (10µM), cisplatin (10µM) or etoposide (10µM) for 24 h at 37 C. Cells were labelled with Annexin and propidium iodide as described by the manufacturer and analysed by flow cytometry.
DNA UV Thermal Melting Studies:
These were performed as previously described [16] . Calf thymus DNA (ctDNA) (Sigma Aldrich, Poole, UK) was exposed to Ag8 and DNA thermal melting curves were determined using a Varian-Cary 400 Bio UV/Vis spectrophotometer, equipped with a Peltier temperature controller. Heating runs were performed between 25 and 99 C, heating at a rate of 1 C min -1 , while continuously monitoring the absorbance at 260 nm. Melting temperatures (Tm) were determined graphically from the primary data using the method of Wilson et al [17] .
Induction of DNA damage in cell free assays:
The ability of Ag8 to directly damage supercoiled plasmid DNA was assessed as described in detail previously [18] . Briefly, supercoiled plasmid DNA was exposed to a range of Ag8 concentrations for 1 h at 37 C, separated on a 1% agarose gel prior to staining with ethidium bromide. Images were captured on a FX phosphoimager using Image Q software (Biorad).
Induction of DNA damage in cells: The induction of DNA damage in A2780 and
A2780cis/CP70 cells was performed using the alkaline and neutral comet assay as previously described [19, 20] . Comets were visualised using an epifluorescent microscope (Nikon Eclipse E800, Japan) with images captured and tail moments determined for 50 randomly selected comets using Comet assay III software (Perceptive Instruments, UK).
Inhibition of topoisomerase I and II:
The effect of Ag8 on topoisomerase activity was determined using human topoisomerase I and II relaxation assays (Inspiralis, Norwich, UK).
Reaction conditions were as specified by the manufacturer with the topoisomerase reaction mix incubated with Ag8 (various concentrations) for 5 min prior to the addition of supercoiled plasmid DNA. The bioreductive prodrug EO9 was used as a positive control for the induction of single strand breaks in DNA [11] . Following a 30 min incubation at 37 C, supercoiled and relaxed plasmid DNA was separated on a 1% agarose gel, stained with ethidium bromide and visualised using Molecular Imager FX (Biorad, Hemel Hempsted, UK).
Inhibition of PARP-1:
The effect of Ag8 and NU1025 on purified PARP-1 activity was determined using the PARP-1 activity assay from Trevigen (Gaithersburg, USA). To assay whether Ag8 inhibits PARP activity in cultured cells, HCT116 colorectal cancer cells were treated with TMZ (1mM) for 2 h to induce SSBs. Cells were washed twice with PBS before a further 15h 'repair' incubation in fresh cell culture medium in the presence or absence of Ag8 (16µM) or NU1025 (100µM). Cells were then stained for S1γ9P HβAX expression according to the manufacturer's instructions (Cell Signalling Technology) and images were acquired using a Leica fluorescent microscope. As inhibition of PARP has been shown to potentiate TMZ activity [21] , HCT116 cells were treated with TMZ (500µM) in the presence or absence of Ag8 or NU1025 and cell survival determined as described above.
Effects on glycolysis: Glycolysis stress tests (extracellular flux analysis [XF]) were
performed using an XF e 96 Analyzer (Seahorse Bioscience) according to the manufacturer's instructions. Briefly, A2780 and OVCAR cells were seeded at 1.5x10 4 and non-cancer ARPE-19 cells were seeded at 3x10 4 cells per well. A range of Ag8 concentrations were added to cells just prior to (acute) or 0.5 h and 1 h before assaying glycolytic activity. Three sequential measurements were used to calculate glycolytic parameters for each test condition.
To normalize data, cells were stained with sulforhodamine B (SRB) to determine cellular protein content.
In vivo activity of Ag8 in the hollow fibre (HF) assay: All animal procedures were
carried out under a project licence issued by the UK Home Office and UK National Cancer Research Institute Guidelines for the Welfare of Animals [22] were followed throughout. A2780, A2780cis/CP70 or OVCAR-3 cells were loaded into sterilised colour-coded PVDF Spectra/Por hollow fibres (Spectrum Medical Inc, Houston, TX, USA) as described previously [23] . Hollow fibres were implanted intraperitoneally (ip) or subcutaneously (sc) and groups of 5 mice were treated with 10 mgkg -1 Ag8 in 10% DMSO: 90% arachis oil administered ip daily on days 3, 4, 5 and 6 post-implantation. Cell survival was assessed as described previously [23] .
Results
Chemosensitivity studies:
As expected, the cisplatin resistant A2780cis/CP70 cell line was significantly (p < 0.01) less responsive to cisplatin than A2780 cells with IC50 values of 6.07 ± 1.78 and 0.73 ± 0.30 M respectively ( Figure 2A ). In contrast, Ag8 was significantly (p < 0.001) more active against the cisplatin resistant A2780cis/CP70 cell line compared to cisplatin sensitive A2780 cells (IC50 values of 0.09 ± 0.01 and 0.44 ± 0.15 M respectively).
Against other cancer cells, a broad range of responses to cisplatin was observed with IC50 values ranging from 0.56 ± 0.γβ M (MDA-MB-468) to 9.γγ ± β.β6 M (MDA-MB-231).
Ag8 showed promising low micromolar activity against all cancer cell lines tested but, with the exception of A2780 and A2780cis/CP70 cells, the range of responses was narrower (6.27 ± 0.39 to 13.34 ± 2.16 M) than for cisplatin.
The activity of Ag8 and cisplatin against ARPE-19, WI38 and PNT2 non-cancer cells is presented in Table S2 and these IC50 values were used to determine the selectivity index presented in Figure 2B . Ag8 exhibited superior selectivity in vitro towards the A2780 and A2780cis/CP70 cells over cisplatin for all three non-cancer cells tested ( Figure 2B ). Similar results were obtained in other cell lines where Ag8 exhibited superior or comparative selectivity to cisplatin ( Figure S1 ). Against the NCI60 tumour cell line panel ( Figure S2 ) no obvious disease specific activity was observed and COMPARE analysis demonstrated that Ag8 does not share a mechanism of action with established anti-cancer drugs including cisplatin. Using the All Synthetic Compounds database however, a correlation coefficient of 0.785 was obtained with Pleurotin, a known inhibitor of Trx-R.
Induction of Oxidative Stress:
In a cell free assay, Ag8 is a potent inhibitor of purified human Trx-R with an IC50 of 2.39 ± 0.59nM ( Figure 3A ). In cells, Trx-R decreases levels of ROS, reducing cellular oxidative stress. The effects of Ag8 on cellular ROS were therefore analysed. Treatment with Ag8 (10 M , 30 min) caused a ~35% increase in ROS compared with a 6% increase with cisplatin (10µM) ( Figure 3B ). Moreover, the anti-oxidant N-acetyl cysteine (NAC) significantly attenuated Ag8 cytotoxicity suggesting that its activity may be partially attributed to Trx-R inhibition and increased ROS production ( Figure 3C ). Ag8 also caused significant and sustained induction of both p-p38 and p-JNK in both A2780 and A2780cis/CP70 cells ( Figure 3D ) whereas the effects of cisplatin on p-p38 and p-JNK were transient or markedly smaller, consistent with the observed weaker ROS induction.
Significantly, prolonged p-p38 and JNK activation can induce downstream signalling pathways leading to cellular apoptosis and as shown in Figure 4 , Ag8 induced significant levels of apoptosis (but not autophagy, Figure S3 ) in both A2780 and A2780cis/CP70 cells.
Ag8 had no effect on HIF1 expression or activity ( Figure S4 ). Figure 5B ). In contrast, extensive SSB and DSB DNA damage was observed in A2780 and A2780cis/CP70 cells exposed to Ag8 as determined by the alkaline and neutral comet assays ( Figures 5C and D) . In contrast to cisplatin, no DNA cross linking was detected in either cell line ( Figures 5E and S6 ). In addition to increased ROS ( Figure 3B) which can result in DNA damage, Ag8 also proved to be a potent inhibitor of topoisomerases in cell-free assays ( Figure 5F ). Ag8 caused a significant dose-dependent inhibition of both human topoisomerase I and II with preferential inhibition of topoisomerase I (complete inhibition at 0.16 M) over topoisomerase II ( Figure 5F ).
Interaction of
Inhibition of PARP-1 by Ag8:
Ag8 is a very potent inhibitor of purified human PARP-1 with a nanomolar IC50 (32 ± 7.6 nM, Figure 6A ). Under identical experimental conditions, NU1025 was ~75-fold less potent (IC50 of β.4 ± 0.β7 M). To determine the effect of Ag8 on PARP-mediated DNA repair in cultured cells, the effects of Ag8 on SSB repair, which is PARP-dependent, were determined following treatment with TMZ ( Figure 6B ). As expected, HCT116 cells treated with TMZ alone showed little or no phosphorylated H2AX ( Figure   6C , negative control). In contrast, for 'repairing' cells incubated in the presence of NU10β5, a clear increase in S139P H2AX positive cells was visible, consistent with inhibition of PARP ( Figure 6D ). Ag8 treatment alone induced some increase in phosphorylated H2AX levels ( Figure 6E ) which is consistent with induction of DSBs as was detected by the neutral comet assay ( Figure 5D ). However, levels of phosphorylated H2AX (S139P) were substantially enhanced in cells treated with TMZ plus Ag8 ( Figure 6F ). Consistent with this, both NU1025 and Ag8 increased the activity of TMZ in drug combination studies ( Figure   6G ).
Inhibition of glycolysis by Ag8:
Ag8 significantly reduced glycolysis and glycolytic reserve in a dose and time dependent manner in A2780 and OVCAR3 cells ( Figures 7A and   B ). In contrast, 1µM Ag8 had no inhibitory effect on glycolysis and glycolytic reserve in confluent, non-replicating ARPE-19 cells ( Figures 7A and B) . A small increase in EACR was however observed in ARPE-19 cells ( Figure 7A ) but this effect was transient and did not reach statistical significance. The effects of Ag8 glycolysis and glycolytic reserve were concentration and exposure time with no acute effects on cell number observed ( Figure S7 and S8).
Anti-tumour activity of Ag8 against ovarian cancers in hollow fibres in vivo:
A single dose of up to 20 mgkg -1 given i.p. or 10 mgkg -1 administered i.p. (daily for 4 days) was well tolerated with no loss in body weight or obvious behavioural signs of distress ( Figure   8B ). A single dose of 25 mgkg -1 (i.p.) was toxic to animals with signs of acute toxicity observed immediately after drug administration. Using the split dose schedule (10 mgkg-1 administered i.p. once per day over 4 days), significant anti-tumour effects were observed against A2780cis/CP70 (p < 0.01), A2780 (p = 0.01) and OVCAR-3 (p < 0.05) fibres implanted intraperitoneally. Using the same schedule however, the response of fibres implanted s.c. did not reach statistical significance ( Figure 8A ).
Discussion:
In the search for multi-targeted anti-cancer drugs, identifying compounds that are both potent and selective towards cancer cells remains a significant challenge. A key finding of this study is that Ag8 has greater or equivalent selectivity to cisplatin in vitro (Figures 2, Figure S1 ). An enhanced level of selectivity can be obtained using non-proliferating, confluent non-cancer cells both in terms of chemosensitivity ( Figure 2 , Table S2 ) and inhibition of glycolysis ( Figure 7) . Moreover, that Ag8 was also well tolerated in vivo (Figure 8) suggests that it has a more favourable toxicological profile than other gold-NHC complexes that have shown toxicity in in vivo models at comparable doses [8] . Ag8 therefore demonstrates selectivity towards cancer cells in vitro (particularly cisplatin resistant A2780cis/CP70 cells) and is well tolerated in vivo, especially when a split-dosing schedule is employed. Its mechanism of action is distinctly different from cisplatin (targeting multiple pathways as opposed to DNA alkylation) and this is likely to account for its ability to induce cytotoxicity in cisplatin resistant A2780 cells.
Ag8 was not tailored to a specific target and therefore a target deconvolution strategy to uncover its mechanism(s) of action was employed. The COMPARE algorithm has an established record of identifying potential mechanisms of action [24] and the chemosensitivity profile of Ag8 correlated well (r 2 = 0.785) with that of pleurotin, a known inhibitor of Trx-R [25] . In cell free assays, Ag8 was a very potent inhibitor of Trx-R with an IC50 value of 2.39 ± 0.59 nM (Figure 3 ). Organometallic compounds are amongst the most potent of Trx-R inhibitors and our results are consistent with these [26] [27] [28] [29] . Mechanistically, the basis for Trx-R inhibition remains undefined but it is known that a seleno-cysteine residue at the C-terminal active site of TrxR constitutes a high affinity binding site for metal ions [30] . Trx-R is an established target for anti-cancer drug discovery [31] [32] [33] and its inhibition impacts upon multiple processes including an increase in reactive oxygen species (ROS), accumulation of the oxidised form of thioredoxin (Trx) and induction of apoptosis [34] . The results presented in Figure 3 are consistent with the inhibition of Trx-R and the induction of apoptosis via the JNK and p38 pathways [35] . It should be noted however that silver-NHC complexes have been shown to induce apoptosis via alternative pathways [36] . In contrast to other Trx-R inhibitors [25, 37] , Ag8 did not alter HIF1 stability or HIF1 function ( Figure   S4 ).
The induction of ROS could contribute to the DNA damage observed in cells treated with
Ag8 although an additional explanation is the ability of Ag8 to inhibit topoisomerases, particularly topoisomerase I ( Figure 5 ). Topoisomerase enzymes are major targets for anticancer drugs [38, 39] and topoisomerase I inhibitors are comparatively rare. Whilst other organometallic complexes have been shown to inhibit topoisomerases [40] [41] [42] [43] [44] , this is the first report documenting the preferential inhibition of topoisomerase I by a silver-NHC complex.
The relative contribution of ROS or inhibition of topoisomerase to DNA damage induction is not known but the induction of DNA damage by at least two different mechanisms may reduce the efficiency of DNA repair. Within the context of DNA repair, this study has demonstrated that Ag8 is a potent inhibitor of PARP-1 in vitro and can potentiate the activity of TMZ ( Figure 6 ). Further studies are required to determine if the potentiation of TMZ activity is cancer selective in vivo and whether Ag8 can induce synthetic lethality in cells that harbour mutations in the BRCA genes.
Finally, metabolic reprogramming is an emerging hallmark of cancer [45] and this study has demonstrated that Ag8 can rapidly and selectively modulate aerobic glycolysis. Ag8 showed inhibitory effects on glycolysis in cancer cells but had no effect on non-proliferating ARPE-19 cells (Figure 7) . Metal-based glycoconjugates including NHC carbene gold(I) complexes are of interest as glycolytic inhibitors [46, 47] but this is the first report describing a silver-NHC complex acting as a glycolytic inhibitor. The precise mechanism(s) by which Ag8 inhibits glycolysis requires further elucidation but the rapid and selective inhibition of the glycolytic phenotype in cancer in preference to non-cancer cells in vitro is promising.
In conclusion, the data presented herein demonstrates that Ag8 has multiple mechanisms of action involving (i) inhibition of Trx-R leading to increased ROS production and subsequently apoptosis (ii) inhibition of topoisomerase I (and to a lesser extent II) leading to DNA damage (iii) inhibition of PARP-1 leading to the potentiation of TMZ activity in vitro and (iv) rapid and selective inhibition of glycolysis in cancer cells. Ag8 is therefore a promising lead compound with (i) multiple mechanisms of action (ii) exhibits a degree of selectivity for cancer over normal cells that is in many instances superior to cisplatin in vitro, (iii) has a mechanism of action that's different from cisplatin and (iv) is well tolerated in vivo and has significant anti-tumour effects in vivo against hollow fibres implanted intraperitoneally (Figure 8 ). The lack of activity against fibres implanted subcutaneaously is likely to be due to the high reactivity of metal NHC complexes with biological thiols and further studies are required to address this issue [48, 49] . In a loco-regional setting however where the aim is to treat tumours that arise in a third compartment, compounds with poor systemic pharmacokinetics may paradoxically be advantageous [50].
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